Virologic outcomes of second-line antiretroviral therapy in Eastern European country of Georgia

AIDS Research and Therapy

Volumn 11, Issue 1, 2014, Pages

  Chkhartishvili, Nikoloz ^a   Sharvadze, Lali ^a,b   Dvali, Natia ^a   Karchava, Marine ^a   Rukhadze, Nino ^a   Lomtadze, Maia ^a   Chokoshvili, Otar ^a   Tsertsvadze, Tengiz ^a,b  

^a Infectious Diseases AIDS and Clinical Immunology Research Center   (United States)

^b TBILISI STATE UNIVERSITY   (Georgia)

Author keywords

Antiretroviral therapy; Eastern Europe; HIV; Second line ART

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GEORGIA (REPUBLIC); HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS INHIBITION; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 84903681897     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-11-18     Document Type: Article

References (22)

1. UNAIDS Global report: UNAIDS report on the global AIDS epidemic 2013 2013, Geneva: UNAIDS, UNAIDS.
2. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007, 44:447-452.
3. Pujades-Rodriguez M, O'Brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. Aids 2008, 22:1305-1312.
4. Hosseinipour MC, Gupta RK, Van Zyl G, Eron JJ, Nachega JB. Emergence of HIV Drug Resistance During First- and Second-Line Antiretroviral Therapy in Resource-Limited Settings. J Infect Dis 2013, 207:S49-S56.
5. Tsertsvadze T, Chkhartishvili N, Sharvadze L, Dvali N, Chokoshvili O, Gabunia P, Abutidze A, Nelson K, Dehovitz J, Del Rio C. Outcomes of Universal Access to Antiretroviral Therapy (ART) in Georgia. AIDS Res Treat 2011, 2011:621078.
6. Chkhartishvili N, Sharvadze L, Chokoshvili O, Bolokadze N, Rukhadze N, Kempker RR, Gamkrelidze A, Dehovitz JA, Del Rio C, Tsertsvadze T. Mortality and Causes of Death Among HIV-Infected Individuals in the Country of Georgia: 1989-2012. AIDS Res Hum Retroviruses 2014, 30:560-566.
7. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 2003, 157:940-943.
8. Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Aids 2012, 26:929-938.
9. Adetunji AA, Achenbach C, Feinglass J, Darin KM, Scarsi KK, Ekong E, Taiwo BO, Adewole IF, Murphy R. Optimizing Treatment Switch for Virologic Failure during First-Line Antiretroviral Therapy in Resource-Limited Settings. J Int Assoc Provid AIDS Care 2012, 12:236-240.
10. Murphy RA, Sunpath H, Castilla C, Ebrahim S, Court R, Nguyen H, Kuritzkes DR, Marconi VC, Nachega JB. Second-line antiretroviral therapy: long-term outcomes in South Africa. J Acquir Immune Defic Syndr 2012, 61:158-163.
11. Patel D, Desai M, Shah AN, Dikshit RK. Early outcome of second line antiretroviral therapy in treatment-experienced human immunodeficiency virus positive patients. Perspect Clin Res 2013, 4:215-220.
12. Schoffelen AF, Wensing AMJ, Tempelman HA, Geelen SPM, Hoepelman AIM, Barth RE. Sustained Virological Response on Second-Line Antiretroviral Therapy following Virological Failure in HIV-Infected Patients in Rural South Africa. PLoS One 2013, 8:e58526.
13. Ferradini L, Ouk V, Segeral O, Nouhin J, Dulioust A, Hak C, Fournier I, Lerolle N, Ngin S, Mean CV, Delfraissy JF, Nerrienet E. High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. J Int AIDS Soc 2011, 14:14.
14. Win MM, Maek-a-nantawat W, Phonrat B, Kiertiburanakul S, Sungkanuparph S. Virologic and Immunologic Outcomes of the Second-Line Regimens of Antiretroviral Therapy Among HIV-Infected Patients in Thailand. J Int Assoc Physicians AIDS Care 2011, 10:57-63.
15. Pujades-Rodriguez M, Balkan S, Arnould L, Brinkhof MA, Calmy A. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA 2010, 304:303-312.
16. Boulle A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, Mathee S, Ford N, Knight L, Osler M, Myers J, Goemaere E, Coetzee D, Maartens G. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. Aids 2010, 24:563-572.
17. Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother 2008, 61:769-773.
18. Castelnuovo B, John L, Lutwama F, Ronald A, Spacek LA, Bates M, Kamya MR, Colebunders R. Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity. J Int Assoc Physicians AIDS Care (Chic) 2009, 8:52-59.
19. Fox MP, Ive P, Long L, Maskew M, Sanne I. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010, 53:500-506.
20. Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, Mhango B, Eron JJ, Phiri S, van Oosterhout JJ. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med 2010, 11:510-518.
21. Charles M, Leger PD, Severe P, Guiteau C, Apollon A, Gulick RM, Johnson WD, Pape JW, Fitzgerald DW. Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti. J Int AIDS Soc 2012, 15:17375.
22. Sarang A, Rhodes T, Sheon N. Systemic barriers accessing HIV treatment among people who inject drugs in Russia: a qualitative study. Health Policy and Plan 2013, 28:681-691.